ANI Pharmaceuticals
ANIP
196 hedge funds and large institutions have $704M invested in ANI Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 82 increasing their positions, 51 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
61% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 51
30% more capital invested
Capital invested by funds: $543M → $704M (+$161M)
16% more call options, than puts
Call options by funds: $7.06M | Put options by funds: $6.07M
6.23% more ownership
Funds ownership: 65% → 71.23% (+6.2%)
3% more funds holding
Funds holding: 190 → 196 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
+$8.11M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.89M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$6.79M |
| 4 |
Renaissance Technologies
New York
|
+$6.32M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$6.12M |
Top Sellers
ANIP Hedge Fund Activity: Q2 2019 in Review
196 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2019, worth a combined $704M — up 30% from $543M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ANIP positions and 13 closed out — a net gain of 8 holders — while 82 added to existing stakes and 51 trimmed.
The largest buyer was Invesco, adding an estimated $8.11M. The largest seller was SG Americas Securities, cutting an estimated $4.21M.
- 196 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2019, up from 190 in Q1 2019.
- Funds reported $704M of ANI Pharmaceuticals stock for Q2 2019, up 30% quarter-over-quarter.
- 21 funds opened new ANI Pharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +8 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2019 was Invesco, an estimated $8.11M added.
- The largest ANI Pharmaceuticals seller in Q2 2019 was SG Americas Securities, an estimated $4.21M sold.
Based on aggregated 13F filings for Q2 2019.